Zyprexa Zydis

Quick links

Choose a section

Quick links to important sections

Advertisements

Zyprexa Zydis

Selected form

Advertisements
Advertisements

Overview of Zyprexa Zydis

Quick Facts

Property Description
Active ingredient Olanzapine
Form Orally Disintegrating Tablet (ODT)
Pharmacological class Atypical Antipsychotic (SGA)
General purpose Mood and Perception Stabilization
Origin Synthetic (Thienobenzodiazepine)

What Type of Medicine is Olanzapine?

Olanzapine is the active ingredient in Zyprexa Zydis, classified as a second-generation antipsychotic (SGA), which falls under the broader category of psychotropic agents. Chemically, it is a synthetic compound derived from the thienobenzodiazepine family. Olanzapine is classified as an atypical antipsychotic, with a primary function in stabilizing conditions characterized by chemical imbalances in the brain. This compound is utilized for its role in helping patients achieve emotional stability and perceptual clarity.


The Orally Disintegrating Tablet (ODT) Form

Zyprexa Zydis is specifically an orally disintegrating tablet (ODT), a key differentiating feature of this presentation. This rapid-dissolving formulation is designed for oral administration and is distinct from standard tablets because it dissolves instantly when placed on the tongue. This specific form, sometimes referred to as a wafer, provides a crucial alternative for patients who may have difficulty swallowing conventional solid medications. Importantly, the ODT form is designed to be bioequivalent to the standard tablet; the Olanzapine ODT formulation is considered interchangeable with the regular tablet. This indicates that the unique, quick-dissolving nature of the Zydis wafer delivers the same amount of Olanzapine into the body as the regular pill.


General Purpose: Rebalancing Brain Chemicals

The drug functions as a selective monoaminergic antagonist, primarily targeting specific receptors for dopamine and serotonin in the brain. By adjusting the activity of these key chemical messengers, Olanzapine's general purpose is to foster mood and perceptual stability. This mechanism is crucial for correcting the underlying chemical imbalances associated with conditions that result in disrupted thought and mood regulation, such as acute episodes of agitation.

Regulatory References

  1. Olanzapine: MedlinePlus Drug Information
Advertisements

What side effects are possible with Zyprexa Zydis?

Official Safety Profile of Olanzapine

The safety profile of Olanzapine, the active ingredient in Zyprexa Zydis, is formally classified by regulatory authorities (such as the EMA and FDA) based on the frequency and type of adverse reactions observed in clinical use.

Frequency-Classified Adverse Reactions

Adverse reactions are organized by the probability of their occurrence:

  • Very Common (ge 1/10): Includes somnolence (drowsiness), significant weight gain, and increased prolactin levels (hyperprolactinemia).
  • Common (ge 1/100 to < 1/10): Includes dizziness, akathisia (inner restlessness), tremor, constipation, orthostatic hypotension (dizziness upon standing), and increases in blood glucose and lipid levels (dyslipidemia).

Orthostatic hypotension and somnolence are generally noted to be more frequent during the initial phase of treatment.

Serious Adverse Reactions and Systemic Concerns

The regulatory labels document rare but serious adverse reactions, including Neuroleptic Malignant Syndrome (NMS), a potentially fatal complex of symptoms. Long-term exposure is associated with the risk of developing Tardive Dyskinesia, a condition involving involuntary, sometimes irreversible, movements. Other serious risks include venous thromboembolism (VTE) and severe hypersensitivity reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Given the documented metabolic effects, official safety information stipulates the requirement for monitoring blood glucose and lipid profiles in all patients.

Population-Specific Safety Notes

The FDA label includes a Boxed Warning regarding the use of Olanzapine in older adult patients with dementia-related psychosis, documenting an increased risk of mortality and cerebrovascular events, such as stroke, in this population. Pediatric patients have been observed to have higher rates of weight gain, elevated lipid levels, and increased prolactin compared to adults.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of olanzapine (the active ingredient in Zyprexa Zydis) requires immediate medical attention. Contacting emergency services is necessary upon recognition of an overdose event.

The officially documented clinical manifestations of overdose commonly involve central nervous system depression, which can range from somnolence and sedation to coma. Other frequent signs reported in regulatory documents include a rapid heart rate (tachycardia), low blood pressure (hypotension), and various extrapyramidal symptoms (involuntary movements). Specific findings like pinpoint pupils (miosis) and speech difficulties (dysarthria) have also been noted.

Overdose is associated with severe, potentially life-threatening outcomes. These complications, as documented in official labeling, include the risk of cardiac arrhythmias, notably QTc prolongation, seizures, and in rare instances, Neuroleptic Malignant Syndrome (NMS) or cardiopulmonary arrest.

There is no specific antidote known to reverse the effects of olanzapine. Consequently, regulatory guidance mandates that treatment must be symptomatic and supportive care. Close medical supervision and continuous monitoring are required for a minimum of 24 hours due to the drug’s extended duration in the body. For the orally disintegrating tablet (Zydis) formulation, regulatory documents note the presence of phenylalanine, which is a specific consideration for individuals with Phenylketonuria (PKU).

Advertisements

Therapeutic Uses of Zyprexa Zydis

The primary therapeutic use of this treatment is for managing severe psychiatric conditions where patients experience a significant symptomatic burden. It is used across clinical domains where additional symptomatic support is needed, specifically addressing Schizophrenia and the acute, mixed, or maintenance phases of Bipolar I Disorder.

The medication helps address symptom clusters that may become intense or disruptive, such as hallucinations, delusions, severe agitation, and extreme mood instability in acute episodes. It supports patients during difficult episodes by easing distress and may assist with maintaining functional stability.

Controlling Psychotic Episodes and Disorganized Thought

This treatment is applied in conditions marked by a profound disruption in thinking and perception. It is used to manage intensely distressing manifestations like disorganized thought, which generally supports a return to mental clarity and helps ease the overall symptomatic burden.


Stabilization of Severe Mood Swings in Bipolar I Disorder

The treatment is relevant for acute and chronic management of Bipolar I Disorder, where it helps moderate the extreme symptomatic patterns of mania and mixed episodes. By helping to stabilize severe emotional intensity and reduce symptoms like racing thoughts and excessive energy, it contributes to a sustained sense of emotional stability and is used for managing the recurrence of these episodes.


Rapid Support for Acute Agitation and Distress

Zyprexa Zydis is commonly used during clinical scenarios where symptoms escalate suddenly, requiring short-term symptomatic assistance to manage acute agitation and behavioral disruption. This application provides supportive relief that may help patients cope more steadily with momentarily overwhelming symptoms.


Symptom Focus: Relief for Severe Symptom Clusters

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Zyprexa Zydis?

Official regulatory bodies define specific population-based rules for the use of Zyprexa Zydis (olanzapine ODT).


Absolute Prohibitions

Use is contraindicated for individuals with a known hypersensitivity to olanzapine or any of its components, and for patients with narrow-angle glaucoma. Due to its phenylalanine content, the Zydis ODT formulation is also contraindicated for patients with Phenylketonuria (PKU). The medicine is not approved and not recommended for the treatment of elderly patients with dementia-related psychosis due to an officially documented increased risk of death.


Eligibility by Age and Status

  • The medicine is approved for adults and adolescents 13 years for specific psychiatric indications. Safety and efficacy are not established for children under 13 years of age.
  • A lower starting dose should be considered for patients with renal impairment or moderate hepatic insufficiency.
  • Use is not recommended for breastfeeding women as the drug passes into human milk, and caution is required for use during the third trimester of pregnancy due to risk of neonatal withdrawal.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Olanzapine, the active ingredient in Zyprexa Zydis, interacts with other substances primarily through metabolic and additive pharmacodynamic mechanisms, as documented by regulatory agencies.

The drug's primary metabolic pathway involves the CYP1A2 enzyme. Co-administration with the CYP1A2 inhibitor Fluvoxamine significantly increases Olanzapine plasma exposure. Conversely, CYP1A2 inducers like Carbamazepine and tobacco smoke accelerate Olanzapine clearance, resulting in reduced exposure.

Pharmacodynamic interactions involve additive effects on the central nervous system (CNS). CNS depressants, including alcohol and certain benzodiazepines, potentiate sedation and orthostatic hypotension. Official documents also caution against combining Olanzapine with agents known to prolong the QTc interval, such as Pimozide and Thioridazine, due to the risk of additive cardiac effects.

A non-enzymatic interaction exists with Activated Charcoal, which significantly reduces oral bioavailability and requires separation of administration. Finally, pharmacokinetic monitoring notes that non-smoking status, female gender, and geriatric age may contribute to slower Olanzapine metabolism and consequently higher concentrations.

Advertisements

Mechanism of Action

Zyprexa Zydis (olanzapine) exerts its pharmacological action through antagonism at multiple G-protein coupled receptors (GPCRs) and monoamine receptors within the central nervous system. Its primary biological targets include the dopamine D2 receptor and the serotonin 5-HT2A receptor. Olanzapine exhibits high affinity for both receptor classes.

Olanzapine functions as an antagonist at the post-synaptic 5-HT2A receptors, blocking the binding of endogenous serotonin. Simultaneously, it acts as an antagonist at dopamine D2 receptors, competitively inhibiting dopamine binding. This dual action modifies the neurotransmitter signaling ratio in key mesolimbic and mesocortical pathways.

The antagonism at 5-HT2A and D2 receptors alters the intracellular signaling cascade, specifically modulating adenylyl cyclase activity and the production of cyclic AMP (cAMP), a second messenger. Downstream, this influences neuronal excitability and gene expression related to synaptic function. The resulting system-level physiological consequence is a generalized modulation of dopaminergic and serotonergic neurotransmission across the forebrain and limbic structures. The drug also possesses high affinity antagonism at several other receptors, including muscarinic M1, histamine H1, and adrenergic alpha1 receptors, contributing to its overall pharmacodynamic profile.

Advertisements

Dosage and Administration Information

How Zyprexa Zydis is Used

The administration of Zyprexa Zydis (olanzapine orally disintegrating tablet) follows specific instructions detailing the method, frequency, and standard dosing ranges. The medicine is prescribed for oral administration and is typically taken once a day. Because the tablet is designed to dissolve rapidly, it can be taken without regard to meals and its absorption is not affected by food.

Administration Procedure

Zyprexa Zydis requires special handling due to its orally disintegrating nature. The wafer must be removed from its packaging using dry hands by peeling back the foil; the tablet should not be pushed through the foil. The entire wafer is placed in the mouth and allowed to dissolve on the tongue before being swallowed, which can be done with or without liquid. If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped. A double dose should not be taken to compensate.

Standard Dosage Regimens

Standard regimens include starting doses and maximum limits for adults. The starting dose for Schizophrenia is often 10 mg once daily, while Bipolar Mania may start at 10 mg or 15 mg once daily. The typical daily range for maintenance is 5 mg to 20 mg, with 20 mg being the maximum daily dose. Dose adjustments, which are typically made in 5 mg increments, are separated by specific time intervals, such as no less than 24 hours.

Population-Specific Considerations

Specific considerations exist for certain patient populations. A lower starting dose of 5 mg per day may be considered for patients who are 65 years and older, as well as those with known hepatic (liver) or renal (kidney) impairment.

Advertisements

Recent Clinical Evidence

Research Evidence: How Studies Evaluated Olanzapine

This overview describes the official research, including Randomized Controlled Trials (RCTs) and systematic reviews, that comprise the evidence base for olanzapine (the active ingredient in Zyprexa Zydis). The focus is on what was measured in these studies and what patterns the evidence describes so far.


Evidence for Use in Schizophrenia

Research exploring Schizophrenia utilized short-term RCTs (typically six weeks) and long-term maintenance trials. The main research focus was examining changes in overall psychotic symptoms (positive and negative) and monitoring the frequency of relapse events. Findings describe patterns observed in studies that reached the criteria for clinical response or symptom remission. Uncertainty remains regarding the availability of robust data for long-term functional outcomes, such as social success, beyond the duration of the short-term trials.


Evidence for Use in Bipolar I Disorder

The evidence base for Bipolar I Disorder consists primarily of short-term RCTs lasting about three to four weeks. These studies were conducted during periods of heightened symptom activity (manic or mixed episodes). Research examined the change in the severity of manic symptoms and monitored the time taken for an episode to recur (time to relapse) in maintenance phases. Follow-up durations for many definitive trials were limited, which is a key consideration for a condition characterized by cycles of stability and flare-ups.


Evidence for Rapid Support in Acute Agitation

Research was specifically designed to explore the unique properties of the orally disintegrating tablet (ODT) formulation in the context of acute agitation. These involved ultra-short term RCTs comparing the ODT formulation to placebo. The primary focus was on measuring the speed and magnitude of change in agitation symptoms. Findings describe patterns observed in the studies as early as 15 minutes post-administration. The follow-up durations for this research were limited, focusing only on symptom control within the first 24 hours.


What Remains Unclear or Under-Researched

The research landscape contains several limitation frames. Studies included adolescents, but the data often consists of observations from adults, which limits the direct applicability of findings to younger populations. Data for groups like older adults with high comorbidity remain insufficient. Furthermore, sample sizes were modest in some subgroup analyses, and the research provides limited context regarding functional measures or personal outcomes beyond group patterns.

Key Studies & References

  1. NICE Guideline CG178: Psychosis and schizophrenia in adults: prevention and management
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Zyprexa Zydis (FAQ)

Q: Does Zyprexa Zydis make you tired or sleepy?

A: Official safety information indicates that drowsiness, which is also referred to as somnolence or sedation, is a Very Common side effect of the active ingredient olanzapine. This means it has been reported to occur in 1 in 10 patients or more. This effect may be more noticeable when first starting treatment.

Q: Is weight gain common when taking Zyprexa Zydis?

A: Yes, significant weight gain is officially described as a Very Common side effect associated with the use of olanzapine. According to official documents, this has been one of the most frequently reported side effects.

Q: Does alcohol interact with Zyprexa Zydis?

A: Regulatory documents advise caution regarding the combination of alcohol with olanzapine. Alcohol may increase the effects of the medicine on the central nervous system (CNS). This can potentially lead to greater sedation, dizziness, or other CNS depressant effects.

Q: How long does the effect of one dose of Zyprexa Zydis last?

A: The half-life of oral olanzapine, which measures how long the medicine takes to decrease by half in the body, averages around 30 hours. Because of this, it is typically administered once a day. With daily dosing, the concentration of the medicine in the body is expected to reach a steady level in about one week.

Q: How quickly does Zyprexa Zydis start working after I take it?

A: The active ingredient typically reaches its peak concentration in the blood around 6 hours after administration, though this can vary among individuals. For the main conditions it treats, clinical trials often show a statistically significant effect within the first week of starting treatment, with clinical trials often observing continued response over the first few weeks.

Q: Can I take Zyprexa Zydis if I have kidney problems?

A: Regulatory documents recommend that official recommendations suggest considering a lower starting dose for patients who have known moderate renal (kidney) impairment.

Q: Is it true that Zyprexa Zydis dissolves very quickly?

A: Yes, the Zydis name is a specialized formulation known as an Orally Disintegrating Tablet (ODT). This form is designed to begin disintegrating in the mouth within seconds. It allows the medication to be easily swallowed with or without liquid.

Q: What kind of mental health issues is Zyprexa Zydis approved for?

A: The medicine is officially indicated for the treatment of schizophrenia. It is also approved for treating manic or mixed episodes associated with bipolar I disorder.

Q: What are the signs of an allergic reaction to Zyprexa Zydis?

A: Any severe reaction, such as a rash, swelling, or difficulty breathing, is described in official safety information as requiring medical attention. Use of the medicine is prohibited (contraindicated) for anyone with a known hypersensitivity to the drug's components, and rare but serious allergic conditions like DRESS syndrome have been documented.

Q: Why might a doctor choose the Zydis ODT over a standard tablet?

A: The Zydis ODT is bioequivalent to the standard tablet, meaning it delivers the same amount of the active ingredient into the body. It is often cited as an alternative for patients who may have difficulty swallowing conventional solid medications, as the ODT formulation dissolves rapidly on the tongue.

Q: Are there any major food or drink restrictions while using Zyprexa Zydis?

A: The medicine can be taken regardless of meals. However, official product information advises caution regarding alcohol use because of the potential for increased sedation. Specific food interactions like grapefruit are not consistently highlighted in core regulatory documents, but caution is always advised when combining medicines with substances that can affect drug metabolism.

Q: Is there a risk of developing diabetes while on Zyprexa Zydis?

A: Official safety information indicates that high blood sugar (hyperglycemia) and the development or worsening of existing diabetes have been reported with olanzapine. Regulatory documents report that these metabolic changes have, on occasion, led to serious conditions such as ketoacidosis or coma. Official safety information stipulates that regular monitoring of blood glucose levels is a requirement when this medicine is used.

Q: Does Zyprexa Zydis affect blood pressure?

A: Yes, one of the Common side effects, especially at the start of treatment, is orthostatic hypotension, which is a drop in blood pressure when standing up. While rare, official documents also note occurrences of high blood pressure (hypertension) or irregular blood pressure in some serious events.

Q: Can older adults take Zyprexa Zydis?

A: The medication is approved for adult use, but regulatory documents recommend considering a lower starting dose for patients aged 65 and over due to population-specific risks. Use of the medicine is officially contraindicated (prohibited) for older adults who have dementia-related psychosis.

Q: Is Zyprexa Zydis safe to use during pregnancy?

A: Safety has not been established in pregnant women. Regulatory documents state that newborn babies exposed to this type of medicine during the last three months of pregnancy are at risk for adverse effects, including neurological or withdrawal symptoms. The decision to use the medicine during pregnancy involves a documented balancing of the potential risks and benefits.

Q: What happens if I forget to take a dose of Zyprexa Zydis?

A: Official administration instructions describe a procedure where a missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the official procedure indicates that the missed dose must be skipped. Regulatory documents state that a double dose must not be taken to compensate for a missed dose.

Q: Is it necessary to drink water after the tablet dissolves?

A: No, the official instructions for Zyprexa Zydis state that after the tablet has fully dissolved on the tongue, it can be swallowed with or without liquid. The rapid-dissolving nature of the tablet makes drinking water optional.

Q: Does using Zyprexa Zydis make it hard to drive or operate machinery?

A: Official labeling cautions that olanzapine has the potential to impair judgment, thinking, and motor skills. The official label cautions users about operating machinery, including driving, until they are reasonably certain the drug does not impair them.

Q: Can Zyprexa Zydis cause involuntary movements or tremors?

A: Yes, tremor (shaking) is listed as a Common side effect. Furthermore, the drug is associated with a risk of developing Tardive Dyskinesia, a serious condition involving involuntary, sometimes irreversible, movements, particularly with long-term exposure.

Q: Are there any long-term health risks associated with taking Zyprexa Zydis?

A: Long-term exposure is associated with several serious risks, including the development of involuntary movements (Tardive Dyskinesia) and metabolic changes (e.g., increased blood glucose and lipid levels). Regular monitoring of patients is stipulated in official safety information.

Q: Are there any known interactions between Zyprexa Zydis and caffeine?

A: Official documents state that the medicine is metabolized by an enzyme called CYP1A2. While caffeine is not specifically listed by name, it is a known inhibitor of this enzyme. Therefore, co-administration of substances that inhibit this enzyme, like caffeine, may alter olanzapine levels in the body.

Q: Is Zyprexa Zydis a controlled substance?

A: No, olanzapine, the active ingredient in Zyprexa Zydis, is not classified as a controlled substance under the U.S. Controlled Substances Act. This indicates that regulatory agencies do not consider it to have a significant potential for abuse or dependence.

Q: Does Zyprexa Zydis cause heart problems?

A: The drug carries a documented risk of QTc prolongation, which is an electrical change in the heart, and orthostatic hypotension (low blood pressure). Caution is advised when the medicine is used in patients with existing cardiovascular disease or a history of congenital long QT syndrome.

Q: Is it normal to feel dizzy when first starting Zyprexa Zydis?

A: Yes, dizziness is officially listed as a Common side effect. Dizziness upon standing (orthostatic hypotension) is specifically noted in regulatory documents as being more frequent during the initial phase of treatment.

Q: Can Zyprexa Zydis be taken with other psychiatric medications?

A: Olanzapine is approved for use in combination with certain other mood stabilizers or antidepressants for specific conditions. However, caution is advised with any combination, particularly with medicines that also affect the central nervous system or have the potential to prolong the QTc interval of the heart.

Q: Are there generic versions of Zyprexa Zydis available?

A: The active ingredient in this medicine, olanzapine, is generally available in generic versions, including orally disintegrating tablet forms. The availability of generic olanzapine ODT products provides interchangeability options for patients.

Q: Does Zyprexa Zydis affect sexual function?

A: Official regulatory-affiliated information indicates that olanzapine can affect hormones and has been linked to sexual side effects. These problems may include a reduced interest in sex (reduced libido) and problems achieving an erection in fewer than 1 in 10 patients.

Q: Is Zyprexa Zydis linked to high cholesterol?

A: Yes, elevated cholesterol levels and other increased lipid (fat) levels in the blood, collectively called dyslipidemia, are officially noted as Common side effects. Official safety information stipulates that regular monitoring of fasting blood lipid levels is a requirement when this medicine is used.

Q: Are there specific age restrictions for Zyprexa Zydis use?

A: The medicine is officially approved for adults and adolescents aged 13 years and older for its specified uses. Its safety and effectiveness are not established for children under 13 years of age.

Q: Does Zyprexa Zydis interact with herbal supplements like St. John's Wort?

A: Official documents specify drug interactions, but general herbal supplements are cautioned against. Regulatory documents note that substances which induce the CYP1A2 enzyme, such as St. John's Wort, may accelerate olanzapine clearance, which could reduce the drug's exposure in the body.

Q: What is the clinical evidence supporting the use of Zyprexa Zydis?

A: The core clinical evidence for the effectiveness of olanzapine comes primarily from short-term randomized controlled trials (RCTs). These studies, typically lasting between three and six weeks, demonstrated efficacy in treating the acute symptoms of schizophrenia and the manic or mixed episodes of bipolar I disorder.

Q: Is Zyprexa Zydis habit-forming?

A: Regulatory agencies do not classify olanzapine as having a significant potential for abuse or dependence, as it is not listed as a controlled substance. It is a psychotropic agent used for the long-term management of conditions.

Advertisements

How should Zyprexa Zydis be stored and disposed of?

How to Store and Dispose of Zyprexa Zydis

Zyprexa Zydis (olanzapine orally disintegrating tablets) requires strict adherence to labeled conditions for storage and disposal to maintain its stability.


Storage Requirements

The medication must be stored at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). It must be kept away from excess heat and moisture and remain in its original container, tightly closed. The tablets must be stored in their sealed blister pack and used immediately after opening the package due to the product's moisture sensitivity.


Safety and Disposal

The medicine must be kept out of the sight and reach of children at all times. Unused or expired Zyprexa Zydis must be disposed of according to local regulatory requirements for medicinal products. It should not be discarded via wastewater or standard household garbage.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zyprexa Zydis found in:

A-Z Index: